News

Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically significant reduction in major cardiovascular events, according to the information provided. READ ALSO: Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? That disconnect matters for companies developing other […]

One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.

Anthropic says Claude identified a novel enzyme system with characteristics reminiscent of CRISPR

CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.

Q2 13F filings show that billionaire Ken Fisher’s Fisher Asset Management opened new positions in CRISPR Therapeutics (NASDAQ: CRSP) and Coinbase Global (NASDAQ: COIN). Fisher’s fund bought 77,960 CRISPR Therapeutics shares valued at about $4.25 million as of June 30. The firm also purchased 9,714 Coinbase shares valued at about $1.42 million. Both stocks were […]

CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.

CRISPR Therapeutics AG (CRSP) closed at $59.03 in the latest trading session, marking a +1.2% move from the prior day.

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.

With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.

Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base.

The average brokerage recommendation (ABR) for CRISPR Therapeutics (CRSP) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

CRISPR Therapeutics (CRSP) is drawing fresh attention as investors digest management’s recent comments on faster CASGEVY uptake and prepare for an earnings update that is expected to show higher revenue and a smaller loss. CRISPR Therapeutics has seen momentum cool recently, with the share price down 5.4% over the past week and 3.2% over the last month, while the 1-year total shareholder return has declined 15.3%. This follows a 3-year total shareholder return of 9.3% and a 5-year total...

CRISPR Therapeutics AG (CRSP) reached $51.8 at the closing of the latest trading day, reflecting a -2.19% change compared to its last close.

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

CRISPR Therapeutics (NASDAQ:CRSP) CEO Sam Kulkarni outlined the company’s commercial and clinical priorities during a Morgan Stanley discussion, highlighting continued adoption of CASGEVY and expected data updates across several pipeline programs by the end of 2026. Kulkarni said the company’s stra

AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.

One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.

One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.

Both companies are approaching milestones that could light a fire under their stocks.

Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The company had fallen out of investor favor; its recovery was impressive.

Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.

CRISPR's expanding pipeline could unlock significantly more value by 2031.

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

We'll know a little more about the company's prospects by the end of the year.

CRISPR Therapeutics stock has climbed in the shorter term but still carries a heavy five year loss, and current valuation checks point to a company that does not clearly screen as either cheap or expensive. For investors looking at CRISPR Therapeutics today, the share price near US$56.82 sits against a mixed valuation read and a long term track record that remains in the red. The stock has fallen 52.9% over 5 years, which means long term holders are still under water despite more recent...

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

Impressive results came out on drugs from Amgen, Arrowhead Pharmaceuticals, and Crispr Therapeutics. Their shares are all lower this week.